Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for hepatocellular carcinoma.

Mindie H Nguyen1, Emmet B Keeffe

  • 1Division of Gastroenterology and hepatology, Department ofMedicine, Santford, California 94304-1509, USA. mindiehn@hotmail.com

Journal of Clinical Gastroenterology
|October 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD.

Hepatology international·2024
Same author

Sex and ethnic disparities in hepatitis B evaluation and treatment across the world.

Journal of hepatology·2024
Same author

Impact of Income-to-Poverty Ratio on Long-Term Mortality of Persons with Chronic Liver Disease in the USA, 1999-2018.

Digestive diseases (Basel, Switzerland)·2024
Same author

Editorial: Redefining liver health-Personalised approach to assessment of serum ALT in clinical practice. Authors' reply.

Alimentary pharmacology & therapeutics·2024
Same author

Editorial: Revisit the causes and long-term outcomes in cirrhosis patients-Authors' reply.

Alimentary pharmacology & therapeutics·2024
Same author

Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real-world U.S. patients, 2003-2021.

Alimentary pharmacology & therapeutics·2024

Early hepatocellular carcinoma (HCC) screening is vital for at-risk patients, improving detection and survival rates. Current recommendations involve regular alpha-fetoprotein tests and ultrasounds for chronic hepatitis and cirrhosis patients.

Area of Science:

  • Hepatology and Oncology
  • Medical Screening Protocols

Background:

  • Hepatocellular carcinoma (HCC) incidence is increasing globally, particularly due to chronic hepatitis C.
  • HCC has a poor survival rate, with limited curative treatment options like surgical resection and liver transplantation.
  • Early detection through screening is crucial for improving patient outcomes and treatment eligibility.

Purpose of the Study:

  • To review current recommendations for hepatocellular carcinoma (HCC) screening.
  • To explain the rationale behind existing HCC screening guidelines.
  • To discuss the challenges in cost-effectiveness research for HCC screening.

Main Methods:

  • Review of current consensus recommendations for HCC screening.
  • Analysis of the etiological factors contributing to HCC prevalence.

Related Experiment Videos

  • Examination of screening modalities including serum alpha-fetoprotein and liver ultrasound.

    • Main Results:

    • Physicians routinely screen high-risk patients despite a lack of official guidelines.
    • Consensus recommends annual/semiannual alpha-fetoprotein for hepatitis B carriers.
    • Twice-yearly alpha-fetoprotein and ultrasound are recommended for chronic hepatitis/cirrhosis patients and those with cirrhosis from any cause.

    Conclusions:

    • Screening offers the best strategy for early HCC detection and improved survival.
    • Current screening practices are based on consensus, aiming to identify HCC in at-risk populations.
    • Further research is needed to address the cost-effectiveness of HCC screening programs.